R2 in the Treatment of Follicular Lymphoma
NCT03715309 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 115
Last updated 2019-07-08
Summary
Lenalidomide Based Immunotherapy in the Treatment of FL
Conditions
Interventions
- DRUG
-
Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 16 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-11-01
- Primary Completion
- 2020-11-01
- Completion
- 2020-11-01
Countries
- China
Study Locations
More Related Trials
-
Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study
NCT04842318 ·Status: UNKNOWN ·Phase: PHASE4
-
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
NCT03789240 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty
NCT04120350 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06651853 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
NCT04481815 ·Status: RECRUITING ·Phase: PHASE2
-
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients
NCT04164368 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
NCT00670358 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
NCT01145495 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma
NCT00509184 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
NCT01829568 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
NCT05846763 ·Status: RECRUITING
-
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
NCT06846489 ·Status: RECRUITING ·Phase: PHASE2
-
Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma
NCT01393756 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
NCT00112931 ·Status: COMPLETED ·Phase: PHASE3
-
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
NCT04989621 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma
NCT04934579 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
NCT00238238 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma
NCT01307605 ·Status: TERMINATED ·Phase: PHASE2
-
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
NCT05506410 ·Status: RECRUITING
-
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
NCT04834024 ·Status: RECRUITING ·Phase: PHASE3
-
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
NCT06549335 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
NCT07299149 ·Status: RECRUITING ·Phase: PHASE2
-
Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)
NCT02303119 ·Status: COMPLETED ·Phase: PHASE3
-
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
NCT07255963 ·Status: RECRUITING ·Phase: PHASE2
-
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
NCT02983097 ·Status: TERMINATED ·Phase: PHASE1/PHASE2